Puthanakit Thanyawee, Thepnarong Nattawan, Chaithongwongwatthana Surasith, Anugulruengkitt Suvaporn, Anunsittichai Orawan, Theerawit Tuangtip, Ubolyam Sasiwimol, Pancharoen Chitsanu, Phanuphak Praphan
Center of Excellence in Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
HIV-NAT Research Laboratory, Thai Red Cross AIDS Research Center, Bangkok, Thailand.
J Virus Erad. 2018 Apr 1;4(2):61-65. doi: 10.1016/S2055-6640(20)30246-6.
The rate of vertical HIV transmission for women at high risk of HIV transmission stands at approximately 7.6%. In the present study we describe infant infection rates in women who had received raltegravir (RAL) intensification during pregnancy to a standard three-drug antiretroviral (ART) regimen in Thailand. This prospective cohort study enrolled HIV-1-positive pregnant women at high risk of vertical transmission, as defined by (1) ART initiation at a gestational age (GA) ≥32 weeks or (2) HIV-1 RNA >1000 copies/mL at GA of 32-38 weeks while on ART. Women received a standard three-drug ART regimen with RAL intensification (400 mg twice daily) until delivery and continued on a three-drug ART regimen after delivery. Plasma HIV-1 RNA testing was performed before intensification and at delivery. Infant HIV-1 status was determined using DNA PCR at birth, and at 1, 2 and 4 months of life. Between February 2016 and November 2017, 154 pregnant women on ART were enrolled into the study with a median CD4 cell count and plasma HIV-1 RNA level of 382 cells/mm and 4.0 log copies/mL, respectively. The three-drug combination consisted of either a lopinavir/ritonavir- (53%) or efavirenz-based (43%) regimen. Median GA at time of RAL initiation was 34 weeks (interquartile range [IQR] 33-36) and median duration was 21 days (IQR 8-34). The proportion of women who had a plasma HIV-1 RNA <50 and <1000 copies/mL at delivery was 45% and 76%, respectively. There were six infants with HIV infection, three in utero and three peripartum. Overall vertical transmission rate was 3.9% (95% confidence interval [CI] 1.4-8.2). The majority of high-risk pregnant women living with HIV-1 who had received RAL intensification achieved viral suppression at delivery with a relatively low rate of vertical transmission. This intensification strategy represents an option for prevention in HIV-positive women at high risk of vertical transmission.
处于HIV传播高风险的女性的垂直HIV传播率约为7.6%。在本研究中,我们描述了泰国在孕期接受拉替拉韦(RAL)强化治疗至标准三联抗逆转录病毒(ART)方案的女性的婴儿感染率。这项前瞻性队列研究纳入了垂直传播高风险的HIV-1阳性孕妇,其定义为:(1)在孕龄(GA)≥32周时开始抗逆转录病毒治疗,或(2)在32-38周孕龄接受抗逆转录病毒治疗时HIV-1 RNA>1000拷贝/mL。女性接受含RAL强化治疗(400mg,每日两次)的标准三联抗逆转录病毒治疗方案直至分娩,并在分娩后继续接受三联抗逆转录病毒治疗方案。在强化治疗前和分娩时进行血浆HIV-1 RNA检测。使用DNA PCR在出生时以及出生后1、2和4个月确定婴儿的HIV-1状态。在2016年2月至2017年11月期间,154名接受抗逆转录病毒治疗的孕妇被纳入研究,其CD4细胞计数中位数和血浆HIV-1 RNA水平分别为382个细胞/mm³和4.0 log拷贝/mL。三联药物组合包括洛匹那韦/利托那韦方案(53%)或依非韦伦方案(43%)。开始使用RAL时的孕龄中位数为34周(四分位间距[IQR] 33-36),持续时间中位数为21天(IQR 8-34)。分娩时血浆HIV-1 RNA<50拷贝/mL和<1000拷贝/mL的女性比例分别为45%和76%。有6名婴儿感染HIV,3名在子宫内感染,3名在围产期感染。总体垂直传播率为3.9%(95%置信区间[CI] 1.4-8.2)。大多数接受RAL强化治疗的HIV-1感染高风险孕妇在分娩时实现了病毒抑制,垂直传播率相对较低。这种强化策略是预防垂直传播高风险HIV阳性女性感染的一种选择。